Vertex to Present at the J.P. Morgan Healthcare Conference on January 7

On January 2, 2019 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported that management will present at the J.P. Morgan Healthcare Conference onMonday, January 7, 2019 at 2:30 p.m. ET (11:30 a.m. PT) (Press release, Vertex Pharmaceuticals, JAN 2, 2019, View Source [SID1234532399]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The audio portion of management’s remarks can be accessed live through Vertex’s website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company’s website.

Quest Diagnostics To Speak At The 37th Annual J.P. Morgan Healthcare Conference

On January 2, 2019 Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, reported that it is scheduled to speak at the 37th Annual J. P. Morgan Healthcare Conference in San Francisco (Press release, Quest Diagnostics, JAN 2, 2019, View Source [SID1234532395]). Stephen Rusckowski, Chairman, President and CEO and Mark Guinan, Executive Vice President and CFO will discuss the company’s vision, goals and two-point strategy to accelerate growth and drive operational excellence. The presentation is scheduled for Tuesday, January 8, 2019 at 7:30 p.m. Eastern Time. Mr. Rusckowski and Mr. Guinan also will participate in a Q&A session moderated by the host analyst.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation and Q&A session will be webcast live during the conference and will be available on the company’s investor relations page which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until February 7, 2019.

Coherus BioSciences Appoints Darlene Horton, M.D., Chief Medical and Regulatory Affairs Officer

On January 2, 2019 Coherus BioSciences, Inc. (Nasdaq: CHRS), reported the addition of Darlene Horton, M.D. as Chief Medical and Regulatory Affairs Officer (Press release, Coherus Biosciences, JAN 2, 2019, View Source [SID1234532391]). She assumed her role on January 1, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very pleased that Dr. Horton has joined the executive team at Coherus," said Denny Lanfear, Chairman, President and CEO of Coherus. "She is a foremost biotechnology leader and clinician with an exceptional track record of delivering value to patients and shareholders."

"I believe there is a significant opportunity to accelerate the development and commercialization of biosimilar products. Coherus is leading the way in expanding access to life-changing biologic medicines while also significantly reducing costs to our healthcare system," said Darlene Horton, M.D. "I am honored to be joining Denny and the team at this exciting time for the company."

Dr. Horton recently was Chief Executive Officer of TulangCo, Inc., and Chief Medical Officer at SMC Biotechnology. Previously, she was President and Chief Executive Officer of Nile Therapeutics, Inc., and Vice President and Co-Chair, Joint Steering Committee between Itero and Allergan, and Co-Founder and Chief Medical Officer of Itero Biopharmaceuticals. Prior to that, she was Chief Medical Officer, Clinical Research and Medical Affairs, Senior Vice President, Clinical Research and Member of Corporate Executive Team at Scios, Inc. (a Johnson & Johnson company), where she also was Head, CV Therapeutic Area Center of Excellence.

Darlene earned her B.S. with Honors in Microbiology, and Doctor of Medicine from University of Florida. She did her internship and residency in the Department of Pediatrics at UCSF, and her Pediatric Cardiology Fellowship at the CV Research Institute of UCSF. She worked as a UCSF Clinical Faculty member in Pediatric Cardiology for 20 years, as a Staff Pediatrician at St. Luke’s Hospital and in the Intensive Care Nursery at Kaiser Hospital in San Francisco, California.

Coherus BioSciences Management to Present at The 37th Annual J.P. Morgan Healthcare Conference

On January 2, 2019 Coherus BioSciences, Inc. (Nasdaq: CHRS), reported that senior management will present at the 37th annual J.P. Morgan healthcare conference on Tuesday, January 8, 2017 at 7:30 a.m. PT being held in San Francisco (Press release, Coherus Biosciences, JAN 2, 2019, View Source [SID1234532390]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at View Source

Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

On January 2, 2019 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, reported that it will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9th at 8:00 a.m. PST/ 11:00 a.m. EST. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will provide a corporate update at the conference (Press release, Mirati, JAN 2, 2019, View Source [SID1234532381]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and made available through the "Investors" section of www.mirati.com, and replays will be made available for 90 days following the events.